Afatinib & Dacomitinib in patients previously treated with EGFR Inhibitors
{"Image DocumentName": "Afatinib & Dacomitinib in patients previously treated with EGFR Inhibitors", "Image ImageDescription": "LUX Ling 1 \u2013 Afatinib vs Placebo. PFS: 3.3 vs. 1.1 months. RR < 10% BR.26 \u2013 Dacomitinib vs Placebo. PFS: 2.7 vs. 1.4 months. RR < 10% Miller et al. Lancet Oncol 2013; Ellis et al. ASCO 2014.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}